Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
about
Weekly induction intraperitoneal chemotherapy after primary surgical cytoreduction in patients with advanced epithelial ovarian cancer.Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspectiveMultimodality treatment strategies have changed prognosis of peritoneal metastasesAbdominal metastases from colorectal cancer: intraperitoneal therapyLong-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group studyUsing pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.Intraperitoneal chemotherapy for ovarian cancerDistinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerDrug delivery systems for intraperitoneal therapyMalignant peritoneal mesothelioma: a reviewPK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study.Intracavitary chemotherapy for malignant disease confined to body cavities.Intracavitary chemotherapy in ovarian cancer-an investigational procedureSingle compartment drug delivery.Evaluation of ototoxicity in patients treated with hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin and sodium thiosulfate.Cancer chemotherapy: new strategies for success.Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer.Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy.Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21.Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment.Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer.Effective Delivery of PEGylated siRNA-Containing Lipoplexes to Extraperitoneal Tumours following Intraperitoneal Administration.Adjuvant therapy in resectable gastric cancerHyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors.Hepatic arterial chemotherapy for metastatic colorectal carcinoma.Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.Pharmacokinetics of the perioperative use of cancer chemotherapy in peritoneal surface malignancy patientsHigh-pressure intrapleural chemotherapy: feasibility in the pig model.Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma.Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional ChemotherapyUpregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinomaIntraperitoneal therapy in the management of ovarian carcinomaLong-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusionsEfficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imagingEnhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role.
P2860
Q25256891-1068FF3F-EA63-43FF-974E-04EE859814EEQ26768408-810EBA9C-124E-4853-8BB3-9D873B15D56FQ26769938-D5EA0FE2-49A9-41E2-A90C-4B58A39501AEQ26772268-6912F3A7-CACE-4466-8B9B-F75381716F4DQ30359356-AD8A77D3-0C18-4A03-8ACC-C230BF848B94Q33416610-0DD246B9-7B92-4680-8241-3DB23DD3E5EDQ33614853-F295A984-F093-4BF5-86DB-68496D0BF8B7Q33704050-43DD6595-7158-4387-9976-C1DBE7BE47FCQ33787894-7BA9AA45-4A7E-497B-B64A-68B3B333BDD3Q33871582-E89D49D0-7819-4B90-8057-9972AF74F54DQ33896659-3B985596-BC8F-413A-A9CC-1BF6E120CD61Q34046589-3EBFAA0B-A99F-41C9-AE3D-CBBD9B5259F2Q34191973-7087BB13-7FDF-4E25-BD1D-E2B4D5625346Q34192003-4FB0864B-7323-4DDE-AED6-D24E2B5F32D1Q34263907-C0BF6B49-7203-418E-BE24-8E561BCCB288Q34401647-94BE3699-ADB9-4A2B-8F06-1CDA81A467F7Q34545133-5046A7DB-EFBB-43CA-A72F-6022B972BAAFQ34577012-F27C18C9-C658-4AE0-97D9-5303EA623C62Q34605976-669E610E-2871-4426-A228-CA88EE0397C6Q34628651-6F376425-CC1C-4450-89AE-7C40D1CD5FD9Q34698278-AC2836B4-0895-4F77-B80F-F0B2C1D52E1FQ35032664-1587A36E-C0AB-4480-BBF1-8BDC0F569BC5Q35100812-ECE860C9-8DE9-4371-87FA-EB3EA7556FCCQ35565968-F1B2F1DD-363D-4A1B-A7C8-BC1DFFDECAB5Q35869447-374A0DB6-00C1-4EF6-A311-9DD06B7AEB99Q35977692-16C05237-F4B0-46BC-B46A-6D7CA714C50EQ36004735-73FA20C0-F7A9-4C7B-9599-6442D37A7744Q36063487-6564CB5C-A9B8-4EF3-879A-56975195FD19Q36092295-94BE811F-6F82-4861-BE99-6975FF47E4E2Q36358324-988F5C04-79CE-401A-AF20-634767ED443DQ36444374-00DA62AB-FFD7-4E06-B438-118A7022E985Q36470056-775C6178-AE48-4D3D-8E85-C8D77B189683Q36607749-807DE65A-D3AA-422D-907A-12A9FB8F349DQ36747377-91429472-1B4A-480D-B57D-24ED6AD8C8CCQ36758933-F4FD59D4-74F7-4CEA-8780-B68046297CEBQ36922664-65B5A151-D07C-4DD4-8CD2-3E1B4631D291Q36987747-141F0BCB-67EB-4A6A-A7C0-A540E8306949Q36997855-8E23F116-5F2A-4166-9C0D-3A7B14828A17Q37023919-F0675482-0E04-4723-BEEE-F212709DE687Q37085878-E4DA5F2C-DAF9-45D2-AF95-D62480F7CA2B
P2860
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
description
1978 nî lūn-bûn
@nan
1978 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1978 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
name
Pharmacokinetic rationale for ...... e treatment of ovarian cancer.
@ast
Pharmacokinetic rationale for ...... e treatment of ovarian cancer.
@en
Pharmacokinetic rationale for ...... e treatment of ovarian cancer.
@nl
type
label
Pharmacokinetic rationale for ...... e treatment of ovarian cancer.
@ast
Pharmacokinetic rationale for ...... e treatment of ovarian cancer.
@en
Pharmacokinetic rationale for ...... e treatment of ovarian cancer.
@nl
prefLabel
Pharmacokinetic rationale for ...... e treatment of ovarian cancer.
@ast
Pharmacokinetic rationale for ...... e treatment of ovarian cancer.
@en
Pharmacokinetic rationale for ...... e treatment of ovarian cancer.
@nl
P2093
P1476
Pharmacokinetic rationale for ...... he treatment of ovarian cancer
@en
P2093
DeVita VT Jr
Dedrick RL
P577
1978-01-01T00:00:00Z